Skip to main content
Premium Trial:

Request an Annual Quote

JCVI Reels in $43M NIAID Contract

NEW YORK (GenomeWeb News) – The J. Craig Venter Institute has landed a $43 million contract from the National Institute of Allergy and Infectious Diseases that will fund the institute's disease and human genomic sequencing efforts, JCVI said today.

JCVI will use the funds, which will be spread over five years, to support its sequencing activities as one of the National Institutes of Health's Genomic Sequencing Centers for Infectious Diseases (GSCID).

JCVI will provide genomics resources to NIAID in a collaboration that will "respond to the needs of the global infectious disease community," the institute said. Researchers at the institute will generate genomic data sets that will be used in development of pathogen countermeasures such as vaccines, therapeutics, diagnostics, and surveillance methods, JCVI said.

"The current worldwide outbreak of H1N1 flu, and the increasing prevalence of new and emerging infectious diseases makes our work more necessary than ever," JCVI Founder and President J. Craig Venter said in a statement.

"Since our first sequencing of the Haemophilus influenzae genome in 1995, to our most recent work in sequencing the isolates from the 2009 H1N1 flu outbreak, JCVI is committed to being a major source for leading edge genomic data and tools to further scientific understanding of the microbial world and how it affects humans," Venter added.